CRNX logo

Crinetics Pharmaceuticals, Inc.

CRNX

CRNX: Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

more

Show CRNX Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of CRNX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CRNX's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Somatostatin modulators and uses thereof Mar. 21, 2023
  • Patent Title: Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof Jan. 31, 2023
  • Patent Title: Nonpeptide somatostatin type 5 receptor agonists and uses thereof Oct. 25, 2022
  • Patent Title: Somatostatin modulators and uses thereof Aug. 16, 2022
  • Patent Title: Formulations of a somatostatin modulator Mar. 08, 2022
  • Patent Title: Somatostatin modulators and uses thereof Nov. 30, 2021
  • Patent Title: Somatostatin modulators and uses thereof Jul. 27, 2021
  • Patent Title: Somatostatin modulators and uses thereof Jun. 08, 2021
  • Patent Title: Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof Apr. 20, 2021
  • Patent Title: Process of making somatostatin modulators Jan. 12, 2021
  • Patent Title: Somatostatin modulators and uses thereof Dec. 29, 2020
  • Patent Title: Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof Sep. 08, 2020
  • Patent Title: Somatostatin modulators and uses thereof Jun. 30, 2020
  • Patent Title: Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof Feb. 18, 2020
  • Patent Title: Process of making somatostatin modulators Nov. 05, 2019
  • Patent Title: Somatostatin modulators and uses thereof Jul. 16, 2019
  • Patent Title: Somatostatin modulators and uses thereof May. 01, 2018
  • Patent Title: Somatostatin modulators and uses thereof Feb. 27, 2018
  • Patent Title: Somatostatin modulators and uses thereof Feb. 20, 2018
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CRNX in WallStreetBets Daily Discussion

CRNX News

Recent insights relating to CRNX

CNBC Recommendations

Recent picks made for CRNX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CRNX

Corporate Flights

Flights by private jets registered to CRNX